SAR 125844 / Sanofi, Ligand - LARVOL DELTA

Feasibility of an explainable AI-based therapeutic recommendation-tool utilizing tumor gene expression profiles in advanced and refractory solid tumors. (ASCO 2022) - P=N/A | "Most frequently proposed drugs among the top 10 were palbociclib, talazoparib, infigratinib in TNBC; bosutinib, sapanisertib, SAR125844 in OC; ipilimumab, cabozantinib, sapanisertib in STS... AI-transcriptional-based therapeutic recommendation-tool OncoKEM is feasible and has the potential to expand personalized cancer treatment in pts with advanced & refractory diseases without tractable genomic alterations. The clinical relevance assessment is planned in an upcoming clinical trial."

Breast Cancer • Oncology • Ovarian Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer • FGFR

MET aberrations across multiple tumor types: Results of a molecular screening program (MOSCATO 01). (ASCO 2017) - P1,P=N/A; "...One patient displaying MET exon 14 donor splice site mutation was treated with crizotinib achieving a rapid and sustained partial response... In this analysis, we saw that MET aberrations are rare in various types of advanced cancers. In selected patients, targeting MET is of clinical interest."

Biomarker • Clinical • Biosimilar • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer

SARMET: Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1; N=100; Active, not recruiting; Sponsor: Sanofi; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Non Small Cell Lung Cancer • Oncology